Zydus Lifesciences introduces biosimilar to protect bone health in cancer patients

Zydus Lifesciences has launched Zyrifa, a Denosumab biosimilar, for treating osteoporosis and preventing skeletal complications in cancer patients. Priced at Rs 12,495, the drug aims to improve access and affordability for patients with bone metastases from various cancers. This initiative supports patients in retaining mobility during their cancer treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qgTzBUI
via IFTTT